BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
Study Phase III, Randomized, Double-dummy, Placebo Controlled, Single-center, of Regarding the Non-inferiority of the Medication BL3000, When Compared to Pantogar® Treatment of Telogen Effluvium in Women.
In the register
The register attaches this trial to BL 3000 (Biolab Sanus Farmacêutica), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 3
- Sponsor
- Biolab Sanus Farmaceutica
- Participants (registry)
- 326
- Start
- January 2023
- Primary completion
- July 2023
- Study completion
- July 2023
- Last registry update
- July 2022
- Countries
- —
Conditions studied: Telogen Effluvium
Interventions: BL 3000, Reference Pantogar, BL3000 Placebo, Pantogar - Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.